Population Analysis and Epidemiological Features of. in Madrid, Spain

Similar documents
SUMMARY. Key words: antibioticresistance, Enterobacteriaceae, ESBL, CTX-M,

To cite this version: HAL Id: hal

Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype

Real-time PCR for detection of the O25b-ST131 clone of and its CTX-M-15-like extended-spectrum β-lactamases

Emergence of a mutl Mutation Causing MLST-PFGE. Discrepancy among Pseudomonas aeruginosa Isolates from. a Cystic Fibrosis Patient

generated by the usage of antimicrobial drugs is absent. She is the author of 14 publications in international journals.

Resistance, Yonsei University College of Medicine, Seoul, Korea; and 2 Department of

Received 30 December 2008; returned 13 February 2009; revised 27 February 2009; accepted 4 March 2009

ESCMID Online Lecture Library

ACCEPTED. Department of Microbiology and Clinical Microbiology, Cerrahpasa Faculty of Medicine, University

Intestinal colonization due to Escherichia coli ST131: risk factors and prevalence

Complex molecular epidemiology of extended-spectrum b-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid

NEXT STEP TO STOP THE SPREAD OF ANTIMICROBIAL RESISTANCE. Patricia Ruiz Garbajosa Servicio de Microbiología Hospital Universitario Ramón y Cajal

Abstract. Introduction

Curing antibiotic resistance in vivo. Muhammad Kamruzzaman

Antimicrobial Agents and Chemotherapy New Data Letter

Ampicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of Escherichia coli Isolates with Different -Lactam Resistance Phenotypes

Ampicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of Escherichia coli Isolates with Different -Lactam Resistance Phenotypes

Detection and molecular characterization of extended spectrum of beta lactamase (ESBL) producing Escherichia coli

Pathogenic bacteria replicate and persevere in ecological niches called reservoirs

Emergence and persistence of integron structures harbouring VIM genes in the Children s Memorial Health Institute, Warsaw, Poland,

Extended-spectrum and CMY-type b-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain

Multi-Locus Variable Number of Tandem Repeat Analysis for Rapid and Accurate Typing of Virulent Multidrug Resistant Escherichia coli Clones

Epidemic Plasmid Carrying bla CTX-M-15 in Klebsiella penumoniae in China

Evaluation of the NCCLS Extended-Spectrum -Lactamase Confirmation Methods for Escherichia coli with Isolates Collected during Project ICARE

Evaluation of the NCCLS Extended-Spectrum -Lactamase Confirmation Methods for Escherichia coli with Isolates Collected during Project ICARE

Genomic epidemiology of bacterial pathogens. Sylvain BRISSE Microbial Evolutionary Genomics, Institut Pasteur, Paris

Ongoing epidemic of bla VIM-1 -positive Klebsiella pneumoniae in Athens, Greece: a prospective survey

Use of Molecular Assays for Resistance Detection

Investigation of Klebsiella pneumoniae Isolates Producing SHV-12 and SHV-11 β-lactamases in Korean Hospitals

Title: Description of the First Escherichia coli Clinical Isolate Harboring Colistin-

H. Wu, B.-G. Liu, J.-H. Liu, Y.-S. Pan, L. Yuan and G.-Z. Hu

Key words: ESBLs; Ceftriaxone; Escherichia coli; MICs; Bacteremia

Are There Non-Carbapenem β-lactam Options for Treating ESBL Infections?

Extended-Spectrum -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

Short-form article. The epidemiological and clinical complexity of amoxicillin-clavulanate-resistant. Escherichia coli

ORIGINAL ARTICLE /j x

ACCEPTED. Centre for Infectious Diseases and Microbiology, University of Sydney 1 and Institute for

inhibitors, clavulanate, inhibitor-resistant b-lactamases, IRT, review

ESCMID Online Lecture Library. by author. Why are some carbapenemases successful? Departamento de Microbiología II Universidad Complutense.

Molecular epidemiology of bloodstreamassociated Escherichia coli ST131 H30-Rx subclone infection in a region with high quinolone resistance

The Prevalence of TEM-1 gene causing resistance to beta-lactam antibiotics in Klebsiella pneumoniae isolates from clinical samples and plasmid curing

Extended Spectrum β-lactamases: Critical Tools of Bacterial Resistance

ACCEPTED. Laboratory Medicine, Kosin University College of Medicine, , 34 Amnam-Dong,

Emergence of Enterobacteriaceae co-producing CTX-M-15, ArmA and PMQR in Poland

64 Mukherjee et al. Int. J. Biosci. 2011

JOHN DEMPSEY HOSPITAL Farmington, Connecticut ANTIBIOTIC SUSCEPTIBILITY PROFILES for INPATIENT Bacterial Isolates

Combatting AMR: diagnostics

Diversity of Escherichia coli Strains Producing Extended-Spectrum -Lactamases in Spain: Second Nationwide Study

Diversity of Escherichia coli Strains Producing Extended-Spectrum -Lactamases in Spain: Second Nationwide Study

Molecular susceptibility testing

Indian J Med Res 140, November 2014, pp

Cloning and Characterization of E. meningoseptica Beta Lactamase

Detection and characterization of extended spectrum β-lactamase producing Escherichia coli from poultry of eastern India

OXA-type beta-lactamases among extended-spectrum cephalosporin-resistant Pseudomonas aeruginosa isolates in a university hospital in southern Taiwan

Prevalence and spread of extendedspectrum b-lactamase-producing Enterobacteriaceae in Ngaoundere, Cameroon. Abstract. Editor: R.

Abstract. Introduction

Application of Different Typing Methods for Detection of Microbial Contamination of Biological Products and Clean Rooms

Extended-Spectrum β-lactamases Producing Escherichia coli Strains Monitored Over 4 Years in The University Hospital in Košice, Slovakia

Detection of aac(6 0 )-Ib-cr in KPC-producing Klebsiella pneumoniae isolates from Tel Aviv, Israel


Contents. 1 Basic Molecular Microbiology of Bacteria... 1 Exp. 1.1 Isolation of Genomic DNA Introduction Principle...

The Laboratory Diagnosis of Enterobacteriaceae that produce Carbapenemases. and Johann DD Pitout 1-3

12 th EURL-AR Workshop

ANTIMICROBIAL SUSCEPTIBILITY INCREASING COMPLEXITY FOR TREATMENT OF URINARY

MOLECULAR TYPING TECHNIQUES

Received 16 September 2005/Accepted 20 September 2005

Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing

Escherichia coli clonal group A causing bacteraemia of urinary tract origin

CME/SAM. Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome?

Characterization of globally spread Escherichia coli ST131. isolates ( )

Comparison of different methods of determining b-lactam susceptibility in clinical strains of Pseudomonas aeruginosa

Curriculum Vitae. Abbas Maleki, Ph.D. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

Spain: Second Nationwide Study. de Microbiología. Hospital Universitario Marqués de Valdecilla, Santander; 5 Departamento

Characterization of the new AmpC beta-lactamase FOX-8 reveals a single. mutation Phe313Leu located in the R2 loop that affects ceftazidime hydrolysis

Evaluation of a Double Synergy Differential Test (DSDT) for differential detection of ESBL and AmpC-type

Rapid and Simple Determination of Ciprofloxacin Resistance in. Clinical Strains of Escherichia coli

PERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI. dr. Agus Eka Darwinata, Ph.D.

Received 24 June 2008/Returned for modification 12 August 2008/Accepted 14 September 2008

Methicillin-resistant Staphylococcus aureus (MRSA)

The biomérieux solution. VITEK2 : A challenge with ESBL ESBL. Karen Bush

5.) Name and describe one gene product in E.coli that is associated with performing each step in the recombination process. (6pts)

Prevalence of SHV β-lactamases in Escherichia coli

Characteristics of the Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolated from a Tertiary Hospital in Daejeon, Korea

Whole Genome Sequence Data Quality Control and Validation

Application of Molecular Techniques to the Study of Hospital Infection

Novel genetic environment of the plasmid-mediated KPC-3 gene detected in Escherichia coli and Citrobacter freundii isolates from China

ACCEPTED. Variant CTX-M-59 in a Neonatal Intensive Care Unit in. Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh,

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 8, September 2014

Acinetobacter baumannii

ORIGINAL ARTICLE /j x. Stroger Jr Hospital, Rush University, Chicago, IL, USA

Determination of Exclusion Effect in Wild Type and Rop Deficient Mutated pbr322 Co-transformations

Characterization of a Large Outbreak by CTX-M-1-Producing Klebsiella pneumoniae and Mechanisms Leading to In Vivo Carbapenem Resistance Development

Comparative in-vitro activity of cefaclor against urinary tract isolates of Escherichia coli

Received 9 January 2007/Returned for modification 1 March 2007/Accepted 24 May 2007

Extended-spectrum b-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system

Sequences of -Lactamase Genes Encoding CTX-M-1 (MEN-1) and CTX-M-2 and Relationship of Their Amino Acid Sequences with Those of Other -Lactamases

Lauren A. Darling1#, Ann M. Evans1, Kathleen A. Stellrecht1,2, Seela M. Nattanmai1,

Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum -Lactamase Detection Method

AAC Accepts, published online ahead of print on 2 June 2008 Antimicrob. Agents Chemother. doi: /aac

Transcription:

JCM Accepts, published online ahead of print on 5 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00608-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. 1 2 3 4 Population Analysis and Epidemiological Features of inhibitor-resistant-tem (IRT) β-lactamases Producing Escherichia coli from both Community and Hospital Settings in Madrid, Spain 5 6 7 Oihane Martín, Aránzazu Valverde, María I. Morosini, Mario Rodríguez-Domínguez, Mercedes Rodríguez-Baños, Teresa M. Coque, Rafael Cantón and Rosa del Campo*. 8 9 10 11 12 Servicio de Microbiología, Hospital Universitario Ramón y Cajal; Unidad de Resistencia a Antibióticos y Virulencia Bacteriana asociada al Consejo Superior de Investigaciones Científicas (CSIC) and CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain 13 14 15 16 *Corresponding author: Mailing address: Servicio de Microbiología, Hospital Universitario Ramón y Cajal. Ctra. Colmenar, Km 9,1. 28034 Madrid. Spain. Phone: 34-91 3368542; Fax: 34-91 3368809; E-mail: rosacampo@yahoo.com 17 18 Short title: IRT β-lactamases producing clinical E. coli isolates. 19 20 Key words: MLST, Plasmid, E. coli, IRT β-lactamases. 21 1

22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 ABSTRACT Punctual mutations in the TEM-1 or TEM-2 genes may lead to the inhibitor-resistant- TEM (IRT) β-lactamases with resistance to β-lactam-β-lactamase-inhibitor combinations and susceptibility to cephalosporins. The aim of this work was to analyze current epidemiology of IRT β-lactamases in contemporary clinical Escherichia coli. Isolates were prospectively collected in our Hospital (2007-2008) from both outpatients (59.8%) and hospitalized patients (40.2%). Genetic relationship was determined by XbaI-PFGE, MLST and phylogenetic group analysis. IRT genes were sequenced and located by hybridization, and the incompatibility group of plasmids were determined. From a total of 3,556 E. coli isolates recovered in the studied period, 152 (4.3%) showed reduced susceptibility to amoxicillin-clavulanate, 18 of them producing IRT enzymes (0.5%). These were mostly recovered from urine (77.8%). High IRT diversity was detected (TEM-30,32,33,34,36,37,40 and 54), and isolates were clonally unrelated but mostly associated with phylogenetic group B2 (55.5%). In 12 out of 16 (75%) isolates bla IRT gene was plasmid located and transferred by conjugation in 9 of them, whereas chromosomal localization was demonstrated in 4 isolates (25%). Size of plasmids ranged from 40 (IncN) to 100 kb (IncFII, IncFI/FIIA), showing different restriction patterns by RFLP. Unlike extended spectrum β-lactamase producers, frequency of IRT-producers remains low in both community and hospital settings, most of them causing urinary tract infection. Although bla IRT genes are mainly associated with plasmids, they can be also located in the chromosome. Despite this situation, clonal expansion and/or gene dispersion was not observed, denoting independent emergence of these enzymes. 2

44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 INTRODUCTION Resistance to β-lactam-β-lactamase inhibitor combinations in Escherichia coli may be due to different mechanisms including TEM-1-penicillinase hyperproduction, constitutive AmpC overproduction or plasmid AmpC production, OXA-type β-lactamase production, permeability deficiencies involving OmpF and/or OmpC porins, inhibitor resistant TEM (IRT)- and complex-mutant TEM (CMT)-like ß-lactamase production, and more recently to carbapenemase production (4). IRT enzymes comprise a group of plasmid-encoding variants of TEM-1 and TEM-2 with decreased affinity to amino-, carboxy-, and ureidopenicillins and altered interaction with class A ß-lactamase inhibitors (6). IRT-producing isolates remain susceptible to cephalosporins, cephamycins, carbapenems and in most cases to piperacillin-tazobactam. They are usually resistant to ampicillin-sulbactam and intermediate or resistant to amoxicillin-clavulanate combinations. IRT enzymes have been previously reported in different organisms such as E. coli, Klebsiella spp., Enterobacter cloacae, Proteus mirabilis, Citrobacter freundii and Shigella sonnei (4), but there are only few recent epidemiological studies concerning these enzymes. Moreover, the population structure of IRT producing E. coli isolates has not been addressed using a multilocus sequence typing (MLST) technique. The aim of this work was to analyze the current epidemiology of IRT β-lactamases in contemporary E. coli isolates with reduced susceptibility to amoxicillin/clavulanate recovered in our hospital from 2007 to 2008. 3

65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 MATERIAL AND METHODS Bacterial isolates. E. coli clinical isolates with reduced susceptibility to amoxicillin-clavulanate (MIC 16/8 mg/l) according to Clinical Laboratory Standards Institute (CLSI) recommendations (9), were prospectively collected between September-2007 and March-2008 in our institution both from outpatients and hospitalized patients. Bacterial identification and antibiotic susceptibility patterns were determined using the semi-automatic WIDER system (Fco. Soria Melguizo, Madrid, Spain), which has been adapted to read MicroScan panels (Dade-MicroScan, West Sacramento, Calif.) (3). Only one isolate per patient was considered. β-lactamase detection, antimicrobial susceptibility testing and phenotype classification. In addition to the WIDER susceptibility testing results, agar dilution and disk diffusion methods with different β-lactam antibiotics and ß-lactamase inhibitors were performed and interpreted according to CLSI guidelines (8), and resistance phenotypes were established following Livermore s recommendations (20). Amoxicillin-clavulanate susceptibility tests were performed using both a fixed 2:1 ratio and 2 mg/l fixed clavulanate concentration by the agar dilution method. Disks (20 µg of amoxicillin and 10 µg of clavulanate) were purchased from Oxoid (Ltd., Basingstoke, England). Isoelectric focusing (IEF). Exponentially growing bacteria at 37 C in Luria- Bertani medium (Difco, St. Louis, MO, USA) were harvested, and cell-free lysates were prepared by sonication. Isoelectric focusing was performed by applying the crude sonic extract to Phast gels (ph 3 to 9) in a Phastsystem apparatus (Pharmacia AB, Uppsala, Sweden). β-lactamases with known pis (pis 5.9, 5.4, 7.6, and 8.1) were used in parallel as controls. Gels were stained with nitrocefin (Oxoid) to identify β-lactamase bands. 4

89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 IRT identification. Total bacterial DNA was obtained with the QIAamp DNA Mini Kit (QiaGen, Hilden, Germany) and 2 µl of DNA were used as template in each PCR reaction. Primers for amplifying bla TEM genes (blatem-f: 5 - ATAAAATTCTTGAAGAC-3 and blatem-r: 5 -TTACCTGCTTAATC-3 ) were used with the following conditions: 1 cycle of 5 minutes at 94ºC; 35 cycles of 1 minute at 94ºC, 1 minute at 50ºC, 1 minute at 72ºC; and a final extension of 10 minutes at 72ºC (22). Amplicons were purified using ExoSAP-IT (Amersham, Bucks, UK) and they were further sequenced using an ABI prism 377 automated sequencer (PE, Norwalk, Conn, US). Nucleotide sequences obtained were compared with those available at NCBI and LAHEY databases. Clonal relatedness. E. coli major phylogenetic groups (A, B1, B2 and D) were determined by multiplex PCR as previously described (7). Moreover, XbaI digested genomic DNA was analyzed by pulsed field gel eletrophoresis (PFGE) using a CHEF- DRIII System (Bio-Rad, La Jolla, Ca, US), under the following conditions: 14ºC, 6V/cm 2, 10-40 s and 24 hours. Genetic diversity among the different band patterns was established using the software Phoretrix 5.0 (Nonlinear Dynamics Ltd, UK) with a dendrograme construction using the UPGMA method (11,16). MLST was carried out using the primers and guidelines specified at the E. coli MLST web site (http://mlst.ucc.ie/). Location of IRT genes and plasmid characterization. A filter mating method using LB agar plates supplemented with 50 mg/l ampicillin was used to obtain transconjugants with IRT gene-containing plasmids. Plasmid size and plasmid typing were carried out in transconjugants comparing RFLP patterns as previously described (1, 31). Plasmids were classified according to their incompatibility group using the PCR replicon-typing scheme described by Carattoli et al. (5) followed by nucleotide 5

114 115 116 sequence of the obtained amplicons and hybridization with specific probes. Location of IRT genes was assessed by hybridization of I-CeuI-digested genomic DNA with bla TEM and 16S rrna gene probes as previously described (19). 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 RESULTS Antibiotic susceptibility and IRT characterization. A total of 3,556 E. coli isolates (46.3% from hospitalized patients and 53.7% from the community) were recovered from clinical samples in our department during the studied period (September- 2007 to March-2008). Reduced susceptibility to amoxicillin-clavulanate was observed in 152 isolates (4.3%), 55 of them were fully resistant and 97 intermediately resistant to this compound. Isolates were mainly recovered from urine (73.6%), followed by blood (9.8%), wounds (5.3%), respiratory secretions (4.6%), and other clinical samples (6.7%) and 59.8% belonged to outpatients and 40.2%. to hospitalized patients. Analysis of the phenotypic β-lactam-resistance pattern of the 152 studied isolates revealed that reduced susceptibility to amoxicillin-clavulanate could be classified by phenotypic analysis as penicillinase TEM-1 hyperproduction (n=92, 61%), extendedspectrum β-lactamase (ESBL) synthesis (n=23, 15%), constitutive AmpC overproduction or plasmid AmpC presence (n=19, 12%), and IRT synthesis (n=18, 12%). None of them were associated with carbapenemase production. Presumptive IRT-producing E. coli isolates represented 0.5% (n=18) of the total 3,556 E. coli isolates studied. Significant discrepancies of clinical categories when using different susceptibility testing methods were observed. The IRT phenotype was detected better when a 2 mg/l fixed clavulanate concentration was used (Table 1), a testing concentration recommended by EUCAST (http://www.eucast.org) Co-resistance with non-β-lactam antibiotics is shown in Table 2. 6

139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 Epidemiological characteristics of IRT-producing isolates are shown in Table 2. Characterization of these enzymes revealed a high diversity; TEM-30 (IRT-2) being the most prevalent (4 patients, 22.2%), followed by TEM-33 (IRT-5) and TEM-54 (3 patients each, 16.7%. Other IRT types identified were: TEM-32 (IRT-3), TEM-37 (IRT-8), TEM- 40 (IRT-11), TEM-34 (IRT-6), and TEM-36 (IRT-7). Resistance to nalidixic acid (55.5%) was more frequently observed in hospitalized (75%) than in community patients (40%). Clonal relatedness. IRT producing E. coli isolates corresponded to phylogroups B2 (10 isolates; 55.5%), D (5 isolates; 27.5%) and A (3 isolates; 16.7%). PFGE-XbaI revealed unique band patterns for each of the 18 isolates. MLST results also confirmed that isolates were clonally unrelated (Table 2). Ten isolates were fit in well-define clonal complex (CC) as CC10, CC12, CC23, CC31, CC38, CC46, and CC95. The other eight strains were singletons, some of them previously reported as ST131, ST117, and ST1035, and three newly described in this work ST1216, grouping in CC38, ST1217, and ST1218 (Figure 1). Plasmid characterization.the bla IRT probe hybridized in a single plasmid in 12 isolates (66.6%) whereas hybridization experiments using I-CeuI-digested genomic DNA allowed us to locate bla TEM-30 (IRT-2), bla TEM-32 (IRT-3), bla TEM-37 (IRT-8) and bla TEM-40 (IRT-11) genes in the bacterial chromosome. No clear hybridization was observed in two isolates. Transference of bla IRT gene by conjugation was only observed in nine isolates (50%). Plasmid size ranged from 40 to 100 kb, all of them showing different restriction patterns. IRT-plasmids displayed positive amplifications for IncF (10 isolates), and IncN (2 isolates) replicons, respectively. Their nucleotide sequenced revealed that both IncN plasmids were homologues to pr46 (accession number A4046276) and showed a 32045 G A mutation while sequences of amplicons from IncF plasmids were identical to either IncFII-pRSB107 (n=6, accession number AJ851089) or to the recently described 7

164 165 pecsf1, IncFI-FIIA-pEC14_114, and P1ESCUM (n=1, accession numbers AP009379, GQ39086, CU928148, respectively) (Table 2). 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 DISCUSSION IRT-producing E. coli isolates recovered in our hospital represent a 0.5% of the total E. coli isolates identified over a 7-month period, and 12% of all E. coli isolates with reduced susceptibility to amoxicillin-clavulanate. Nearly 80% of the isolates caused urinary tract infections, mainly in the community setting. Unlike ESBL-producing E. coli, the number of IRT-producers has not substantially increased over time in our country (24). Different factors may have influenced this scenario including probable less selective pressure exerted by β-lactam-β-lactamase inhibitor combinations when compared with that of extended spectrum cephalosporins. This was particularly addressed in our study where a polyclonal nature of population structure was demonstrated. The IRT phenotype confers resistance to β-lactam-β-lactamase-inhibitor combinations whereas the activity of cephalosporins normally remains unchanged. Detection of this phenotype is usually complicated due to the low resistance level to amoxicillin-clavulanate combinations (26). The best approach to detect IRT phenotype is using 2 mg/l- fixed clavulanate concentration (Table 1), although other authors have used ampicillin/sulbactam combinations (4,26). Nevertheless, our phenotypic approach may have some limitations to detect IRT producers due to the inconsistency of the IRT phenotype when other resistant mechanisms are present, such as TEM-1 or other broad spectrum β-lactamase, the concomitant presence of an ESBL or even when the IRT enzyme is hyper-produced or is present in a porin deficient isolate. Recently, the increment of ciprofloxacin resistant ESBL-producer isolates, mostly of CTX-M type has been associated with specific epidemic multiresistant uropathogenic 8

189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 E. coli clones which also include some of the clones identified in our study (28). Nevertheless, a great variety of ST were observed, including seven CCs and six singleton clones, three of them newly described in this work. A remarkable variety of MLST types among Spanish ESBL-producing E. coli isolates was also observed in a recent study (27), the most prevalent corresponding to CC10, CC23, ST131 and ST167, some of which were associated with our IRT-producing isolates. ST131 was the most represented with three isolates followed by CC12 and CC95 with two isolates each. ST131-B2 is widely disseminated among both community and hospital patients and also in healthy persons and companion animals (15,18,29). This clone corresponds to a widespread uropathogenic E. coli strain causing urinary tract infections and bacteremia (17,33-34), and represents 3 out of 18 isolates (17%) of our collection. This result denotes that other factors than clonality might have influence in the low representation of IRT producers, including plasmid epidemiology, emergence of mutations leading the IRT phenotype, or even fitness cost associated to these mutations. The most prevalent phylogroup among the community IRT isolates was group B2 (55%), followed by group D (28%) and group A (17%). Oteo et al. recently reported that ESBL-producing E. coli isolates in Spain usually correspond to the phylogroup A (40%) followed by group B1 (28%), group D (18%) and finally group B2 (14%) (27). B2 is mainly associated with extraintestinal pathogenic strains from the community and is frequently overrepresented in ESBL studies (2,33). In our collection, B2 is represented in both community (all from urine samples) and hospital (2 from urine, 2 from blood and 1 from respiratory secretions) origins. Antibiotic resistance is also frequently linked to B2 group although in our case only resistance to nalidixic acid, ciprofloxacin or trimethoprim-sulfamethoxazole was observed, mostly in the nosocomial isolates. None of the 18 isolates showed resistance to aminoglycosides. 9

214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 The high variety of IRT enzymes found in our study, eight different types in 18 E. coli unrelated clinical isolates, demonstrates an independent emergence of these enzymes but with less propensity of transmissibility or a selectable nature than ESBL producing isolates. Chromosomal location of bla IRT gene was demonstrated in four community isolates, a situation that has been scarcely described for TEM-type β-lactamases (19), and non-previously described for IRT-enzymes. Plasmids containing bla IRT gene were identified as the narrow host range IncF (n=7) or the broad-spectrum IncN (n=2) plasmids. Recently, Marcadé et al. confirmed that IRT β-lactamases are mainly carried by IncF plasmids, sharing the bla TEM-1 genes replicons, which contrarily to bla IRT replicons, successfully disseminated in E. coli isolates around the world (23). Most of the IncF plasmids identified in our isolates have identical nucleotide sequence in the amplified replicon (6 out of 7) and fit with the previously described IncFII prsb107 (30). The first description of this plasmid was in uncultured bacterium from a sewage-treatment plant, and it had a 120-592 pb size. In our case, we observed different plasmid sizes, from 60 to 145 bp, but no additional antibiotic-resistance determinants were observed. One strain carried an IncFI/FIIA bla IRT -plasmid that matched with the pecsf1, pec14-114 and p1escum plasmids obtained from human commensally and uropathogenic E. coli strains (10,12,32). Finally, the bla IRT -plasmids of two strains corresponded to the previously described IncN-pR46 which is linked to antibiotics resistance, but in our case a 32045 G A mutation was observed (13,14,25). In summary, unlike ESBL-producers, frequency of IRT-producing isolates remains low in both community and hospital settings. Epidemiological characteristics of these isolates correspond to unrelated strains, most of them causing urinary tract infection, associated with the B2 phylogroup. Although bla IRT genes are mainly associated to either IncF or IncN plasmids, they can be also located in the chromosome. Despite this situation, 10

239 240 241 clonal expansion and/or plasmid dispersion was not observed in our study. Moreover, the high variety of IRT enzymes within a complex population structure also denotes independent emergence of these enzymes. 242 243 244 245 246 247 248 249 250 ACKNOWLEDGMENTS RdC has a contract from the Spanish Ministry of Health (CB05/137). MJR-D has a Post-MIR contract from the FIBIO-HRyC foundation. MR-B has a contract from the Instituto de Salud Carlos III (FIS), project AI07/90034. AV has a contract with the CIBERESP. This work was partially funded by a research grant from the CIBER en Epidemiología y Salud Pública (CIBERESP) and by the European Project TROCAR (HEALTH-F3-2008-223031). 251 252 253 254 255 256 257 258 259 260 261 262 263 REFERENCES 1. Barton, B. M., G. P. Harding, and A. J. Zuccarelli. 1995. A general method for detecting and sizing large plasmids. Anal Biochem. 226:235-240. 2. Blanco, M., M. P. Alonso, M. H. Nicolas-Chanoine, G. Dahbi, A. Mora, J. E. Blanco, C. López, P. Cortés, M. Llagostera, V. Leflon-Guibout, B. Puentes, R. Mamani, A. Herrera, M. A. Coira, F. García-Garrote, J. M. Pita, and J. Blanco. 2009. Molecular epidemiology of Escherichia coli producing extended-spectrum β- lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 63:1135-1141. 3. Cantón, R., M. Pérez-Vázquez, A. Oliver, B. Sánchez Del Saz, M. O. Gutiérrez, M. Martínez-Ferrer, and F. Baquero. 2000. Evaluation of the Wider system, a 11

264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 new computer-assisted image-processing device for bacterial identification and susceptibility testing. J. Clin. Microbiol. 38:1339-1346. 4. Cantón, R., M. I. Morosini, O. M. de la Maza, and E. G. de la Pedrosa. 2008. IRT and CMT β-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 14 Suppl 1:53-62. 5. Carattoli, A., A. Bertini, L. Villa, V. Falbo, K. L. Hopkins, and E. J. Threlfall. 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 63:219-228. 6. Chaïbi, E. B., D. Sirot, G. Pauland, and R. Labia. 1999. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43:447-458. 7. Clermont, O., S. Bonacorsi, and E. Bingen. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66:4555 4558. 8. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved Standard. Eight edition. Document M07-A8. Wayne. PA. 9. Clinical and Laboratory Standards Institute. 2009. Performance and standards for antimicrobial susceptibility testing. Nineteen informational supplement. Document M100-S19. Wayne, PA. 10. DebRoy, C., M. S. Sidhu, U. Sarker, B. M. Jayarao, A. L. Stell, N. P. Bell, and T. J. Johnson. 2010. Complete sequence of pec14_114, a highly conserved IncFIB/FIIA plasmid associated with uropathogenic Escherichia coli cystitis strains. Plasmid 63:53-60. 12

288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 11. Duck W. M., C. D. Steward, S. N. Banerjee, J. E. Jr. McGowan, and F. C. Tenover. 2003. Optimization of computer software settings improves accuracy of pulsed-field gel electrophoresis macrorestriction fragment pattern analysis. J. Clin. Microbiol. 41:3035-3042. 12. Genoscope -, C.E.A. 2008. Direct submission to the NCBI database of Escherichia coli UMN026 genome sequence project. Accession number CU928148. 13. González-Zorn, B., A. Catalan, J. A. Escudero, L. Domínguez, T. Teshager, C. Porrero, and M. A. Moreno. 2005. arma and aminoglycoside resistance in Escherichia coli. Emerg. Infect. Dis. 11:954-956. 14. Guerineau, J. F., P. M. Mullineaux, and E. W. Parnell. Patent: EP 0369637-A 1 23-May-1990. Sulfonamide resistance genes and their use. Advanced technologies (Cambridge) ltd.; agricultural genetics company limited; biotal limited; bp nutrition ltd; ciba-geigy plc; imperial chemical industries plc; rhone-poulenc ltd; schering agrochemicals limited; shell research limited; twyford seeds ltd; unilever U.K. central resources ltd. 15. Johnson, J. R., S. Miller, B. Johnston, C. Clabots, and C. Debroy. 2009. Sharing of Escherichia coli sequence type ST131 and other multidrug-resistant and urovirulent E. coli strains among dogs and cats within a household. J. Clin. Microbiol. 47:3721-3725. 16. Kaufmann, M. E. 1998. Pulsed-field-electrophoresis, p. 33-50. In Woodford N, Johnson AP (ed.), Molecular bacteriology. Protocols and clinical applications. Humana Press, Totowa, N.J. 17. Lau, S. H., S. Reddy, J. Cheesbrough, F. J. Bolton, G. Willshaw, T. Cheasty, A. J. Fox, and M. Upton. 2008. Major uropathogenic Escherichia coli strain isolated 13

312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 in the northwest of England identified by multilocus sequence typing. J. Clin. Microbiol. 46:1076-1080. 18. Leflon-Guibout, V., J. Blanco, K. Amaqdouf, A. Mora, L. Guize, and M. H. Nicolas-Chanoine. 2008. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J. Clin. Microbiol. 46:3900-3905. 19. Lescat, M., A. Calteau, C. Hoede, V. Barbe, M. Touchon, E. Rocha, O. Tenaillon, C. Médigue, J. R. Johnson, and E. Denamur. 2009. A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A. Antimicrob. Agents Chemother. 53:2283-2288. 20. Livermore, D.M. 1995. beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584. 21. Liu, S. L., A. Hessel, and K. E. Sanderson. 1993. Genomic mapping with I-Ceu I, an intron-encoded endonuclease specific for genes for ribosomal RNA, in Salmonella spp., Escherichia coli, and other bacteria. Proc. Natl. Acad. Sci. USA 90:6874-6878. 22. Mabilat, C., and S. Goussard. 1995. PCR detection and identification of genes for extended-spectrum ß-lactamases, p. 553-557, In Persing DH, Smith TF, Tenover FC, Whiote TJ (ed.), Diagnostic Molecular Microbiology. Principles and Applications, American Society for Microbiology, Washington, DC. 23. Marcadé, G., C. Deschamps, A. Boyd, V. Gautier, B. Picard, C. Branger, E. Denamur, and G. Arlet. 2009. Replicon typing of plasmids in Escherichia coli producing extended-spectrum β-lactamases. J. Antimicrob. Chemother. 63:67-71. 14

336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 24. Miró, E., F. Navarro, B. Mirelis, M. Sabaté, A. Rivera, P. Coll, and G. Prats. 2002. Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant β-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period. Antimicrob. Agents Chemother. 46:3991-3994. 25. Novais, A., R. Cantón, R. Moreira, L. Peixe, F. Baquero, and T. M. Coque. 2007. Emergence and dissemination of Enterobacteriaceae isolates producing CTX- M-1-like enzymes in Spain are associated with IncFII (CTX-M-15) and broad-hostrange (CTX-M-1, -3, and -32) plasmids. Antimicrob. Agents Chemother. 51:796-799. 26. Oliver, A., M. Pérez-Vázquez, M. Martínez-Ferrer, F. Baquero, L. de Rafael, and R. Cantón. 1999. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes. Antimicrob. Agents Chemother. 43:862-867. 27. Oteo, J., K. Diestra, C. Juan, V. Bautista, A. Novais, M. Pérez-Vázquez, B. Moyá, E. Miró, T. M. Coque, A. Oliver, R. Cantón, F. Navarro, J. Campos; and Spanish Network in Infectious Pathology Project (REIPI). 2009. Extendedspectrum β-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/a, ST23 complex/a and ST131/B2. Int. J. Antimicrob. Agents 34:173-176. 28. Pitout, J. D., D. B. Gregson, L. Campbell, and K. B. Laupland. 2009. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli causing bacteraemia in the Calgary Health Region 2000-07: the emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 53:2846-2851. 15

360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 29. Pomba, C., J. D. da Fonseca, B. C. Baptista, J. D. Correia, and L. Martínez- Martínez. 2009. Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrb2 and aac(6')-ib-cr genes in a dog. Antimicrob. Agents Chemother. 53:327-328. 30. Szczepanowski, R., S. Braun, V. Riedel, S. Schneiker, I. Krahn, A. Pühler, and A. Schlüter. 2005. The 120.592 bp IncF plasmid prsb107 isolated from a sewagetreatment plant encodes nine different antibiotic-resistance determinants, two ironacquisition systems and other putative virulence-associated functions. Microbiology 151:1095-1111. 31. Threlfall, E. J., and N. Woodford. 1995. Plasmid profile typing and plasmid fingerprinting. Methods Mol. Biol. 46:225-236. 32. Toh, H., K. Oshima, A. Toyoda, Y. Ogura, T. Ooka, H. Sasamoto, S. H. Park, S. Iyoda, K. Kurokawa, H. Morita, K. Itoh, T. D. Taylor, T. Hayashi, and M. Hattori. 2010. Complete genome sequence of the wild-type commensal Escherichia coli strain SE15, belonging to phylogenetic group B2. J. Bacteriol. 192:1165-1166. 33. Woodford, N., A. Carattoli, E. Karisik, A. Underwood, M. J. Ellington, and D. M. Livermore. 2009. Complete nucleotide sequences of plasmids pek204, pek499, and pek516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob. Agents Chemother. 53:4472-4482. 34. Yumuk, Z., G. Afacan, M. H. Nicolas-Chanoine, A. Sotto, and J. P. Lavigne. 2008. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 62:284-288 16

1 2 Table 1. Results obtained with the different susceptibility methods used to test the 18 IRT producing E. coli isolates. Method % of isolates (No.) Susceptible Intermediate Resistant Microdilution (2:1) a 0 77.8 (14) 22.2 (4) Agar dilution (2:1) a 11.1 (2) 50 (9) 38.9 (7) Agar dilution (2 mg/l) b 0 27.8 (5) 72.2 (13) Disk diffusion (10 µg) 5.5 (1) 33.3 (6) 61.2 (11) 3 4 a: fixed ratio (amoxicillin:clavulanate). b: fixed concentration of clavulanate. 5 6 1

Table 2. Epidemiological characteristics of IRT-producing isolates. IRT Isolate Phylogroup MLST Origin Source TEM-30 (IRT-2) 5.2 Antibiotic resstance bla IRT location Plasmid size (kb) b WT TC Conjugation Replicon type transfer 10924 B2 ST131 Hospital Respiratory Nal, Cip Plasmid 60, 7, 5 50, 7, 5 IncFII + 44965 B2 ST12 (CC12) Community Urine Chromosome 50-29904 D ST38 (CC38) Hospital Respiratory SxT Plasmid 100, 45 IncF c - 46836 D ST393 (CC31) Community Urine Plasmid NO a 40 IncN + TEM-32 (IRT-3) 5.4 TEM-33, (IRT-5) 5.4 34351 B2 ST1045 Hospital Blood SxT Plasmid 145, 48 145, 48 IncFII + 161490 A ST46 (CC46) Community Urine Chromosome 97-45995 B2 ST95 (CC95) Hospital Blood Nal, Cip Plasmid 97, 30 97 IncFII + 20561 B2 ST131 Hospital Urine Nal, Cip, SxT Plasmid 70 60 IncFII + 127618 D ST12 (CC12) Community Urine Nal, Cip NO a 100 - TEM-34 (IRT-6) 5.4 132028 D ST1216 (CC38) Hospital Urine Nal, Cip Plasmid 145, 30 IncFIB/FIIA - TEM-36 (IRT-7) 5.2 41392 A ST617 (CC10) Community Urine Nal, Cip Plasmid 97, 48 97,48 IncFII + TEM-37 (IRT-8) 5.2 TEM-40 (IRT-11) 5.4 43340 B2 ST131 Community Urine Plasmid 97, 40 IncFII - 18204 D ST117 Community Urine Nal Chromosome 97-162266 A ST393 (CC31) Hospital Urine Nal, Cip, SxT NO a NO a IncF c - 47499 B2 ST1217 Community Urine SxT Chromosome 97, 40 - TEM-54 5.4 138942 B2 ST1218 Hospital Urine SxT Plasmid 50, 30, 20 50 IncN + 115819 B2 ST95 (CC95) Community Urine Nal, Cip, SxT Plasmid 145, 60 145, 50 IncFII + 133972 B2 ST88 (CC23) Community Urine Plasmid NO a 50, 15 + a NO: not obtained due to continuous DNA degradation; b. Plasmid size determined by hybridization of S1-digested DNA, c. Double sequence. WT: Wild type. TC: Transconjugant. Underlined corresponds to plasmids with bla IRT positive hybridization. 2

1 ST95 CC95 2 2 isolates ST393 CC31 3 2 isolates ST131 3 isolates 4 ST117 5 ST93 6 CC10 ST167 ST617 7 8 ST46 CC46 9 ST38 ST1216 10 CC38 ST88 11 12 ST1045 ST1217 ST1218 ST12 CC12 2 isolates ST617 CC10 CC23 13 Figure 1. Population structure analyzed by eburst of E. coli based on MLST database. STs identified in this study are indicated.